The historical rank and industry rank for BridgeBio Oncology Therapeutics's EV-to-FCF or its related term are showing as below:
BBOT'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.35 Med: 0 Max: 0
Current: -3.25
BBOT's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.3
vs BBOT: -3.25
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BridgeBio Oncology Therapeutics's PE Ratio (TTM) for today is calculated as:
BridgeBio Oncology Therapeutics's share price for today is $8.40.
BridgeBio Oncology Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-527.989.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BridgeBio Oncology Therapeutics EV-to-FCF Related Terms
BridgeBio Oncology Therapeutics EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Oncology Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BridgeBio Oncology Therapeutics's EV-to-FCF falls into.
BridgeBio Oncology Therapeutics's current Enterprise Value is $424.07 Mil.
BridgeBio Oncology Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-130.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Oncology Therapeutics (BBOT) has a EV-to-FCF of -3.25 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 330 companies in the Biotechnology industry.
Is BridgeBio Oncology Therapeutics' EV-to-FCF too high?
BridgeBio Oncology Therapeutics' current EV-to-FCF is -3.25. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' EV-to-FCF compare to FTH and MNPR?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #999999 out of 330 companies for EV-to-FCF. This places BridgeBio Oncology Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.30, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BridgeBio Oncology Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Oncology Therapeutics's current EV-to-FCF is -3.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current EV-to-FCF of -3.25. The current EV-to-FCF is -3.25. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current EV-to-FCF is -3.25 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BridgeBio Oncology Therapeutics Business Description
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score
Get the complete analysis for BBOT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBOT has been successfully added to your 
